Nektar Therapeutics

Nektar Therapeutics

NKTR· Manufacturing· Fiscal year ends in December

CEO pay in FY2022Stock -83.3% in FY2022

Howard W. Robin is the CEO of Nektar Therapeutics and was paid $11.3M in FY2022 (Dec), up 1%.

Pay$100 in the stock at the end of FY20 → $13
CEO pay is from each Nektar Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives4

See all
  1. 1Howard W. RobinFY2022
  2. 2Mark A. WilsonFY2022
  3. 3Jonathan Zalevsky, Ph.D.FY2022
  4. 4Sandra GardinerNot disclosed

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Nektar Therapeutics paid its 4 named executives $24.8M in total in FY2022 (Dec). CEO Howard W. Robin was paid $11.3M of that.

Name
Howard W. RobinPresident and Chief Executive Officer
Mark A. WilsonFormer Chief Legal Officer
Jonathan Zalevsky, Ph.D.Chief Research and Development Officer

of each named executive, from the Summary Compensation Table of each proxy.

Peers19

See all

The FY2025 (Dec) proxy of Nektar Therapeutics names 19 peer companies for pay. Among Nektar Therapeutics and these peers, CEO pay was 7th highest of 13 and total shareholder return was 12th highest of 13.

7th highest of 13in Nektar Therapeutics and its pay peers, FY2025 (Dec) by CEO pay:

$2.3M$9.7M

12th highest of 13in Nektar Therapeutics and its pay peers, FY2025 (Dec) by total shareholder return:

$17$1,020

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board2

See all
  • R. Scott GreerDirector · 15 yr on the boardIndependentAudit, Nominating and Corporate Governance, Organization and Compensation—Paid as an executive
  • Jeff AjerDirector · 8 yr on the boardIndependentAudit, Organization and Compensation—Paid as an executive

The board of the latest proxy (FY2025).

Activity

Filings6

See all
Proxy statementDEF 14AApr 24, 2026FY2025
Annual report10-KMar 13, 2026FY2025
Proxy statementDEF 14AApr 25, 2025FY2024
Annual report10-KMar 14, 2025FY2024
Proxy statementDEF 14AApr 26, 2024FY2023
Annual report10-KMar 5, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data